6JC2
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 6jc2 by Molmil](/molmil-images/mine/6jc2) | Crystal structure of the Fab fragment of ipilimumab | Descriptor: | SULFATE ION, ipilimumab fab heavy chain, ipilimumab fab light chain | Authors: | Heo, Y.S. | Deposit date: | 2019-01-27 | Release date: | 2019-09-11 | Method: | X-RAY DIFFRACTION (2.65 Å) | Cite: | Crystal Structure of the Fab Fragment of an Anti-CTLA-4 Antibody, Ipilimumab, Used for Cancer Immunotherapy Bull.Korean Chem.Soc., 40, 2019
|
|
5GGS
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 5ggs by Molmil](/molmil-images/mine/5ggs) | PD-1 in complex with pembrolizumab Fab | Descriptor: | Programmed cell death protein 1, heavy chain, light chain | Authors: | Heo, Y.S. | Deposit date: | 2016-06-16 | Release date: | 2016-11-09 | Last modified: | 2016-11-16 | Method: | X-RAY DIFFRACTION (1.997 Å) | Cite: | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy Nat Commun, 7, 2016
|
|
5GGV
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 5ggv by Molmil](/molmil-images/mine/5ggv) | CTLA-4 in complex with tremelimumab Fab | Descriptor: | Cytotoxic T-lymphocyte protein 4, heavy chain, light chain | Authors: | Heo, Y.S. | Deposit date: | 2016-06-16 | Release date: | 2016-11-09 | Last modified: | 2016-11-16 | Method: | X-RAY DIFFRACTION (1.998 Å) | Cite: | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy Nat Commun, 7, 2016
|
|
5GGR
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 5ggr by Molmil](/molmil-images/mine/5ggr) | PD-1 in complex with nivolumab Fab | Descriptor: | Programmed cell death protein 1, heavy chain, light chain | Authors: | Heo, Y.S. | Deposit date: | 2016-06-16 | Release date: | 2016-11-09 | Last modified: | 2016-11-16 | Method: | X-RAY DIFFRACTION (3.3 Å) | Cite: | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy Nat Commun, 7, 2016
|
|
7ERR
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 7err by Molmil](/molmil-images/mine/7err) | |
5GGU
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 5ggu by Molmil](/molmil-images/mine/5ggu) | Crystal structure of tremelimumab Fab | Descriptor: | heavy chain, light chain | Authors: | Heo, Y.S. | Deposit date: | 2016-06-16 | Release date: | 2016-11-09 | Last modified: | 2016-11-16 | Method: | X-RAY DIFFRACTION (2.292 Å) | Cite: | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy Nat Commun, 7, 2016
|
|
5GGT
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 5ggt by Molmil](/molmil-images/mine/5ggt) | PD-L1 in complex with BMS-936559 Fab | Descriptor: | IGK@ protein, IgG H chain, Programmed cell death 1 ligand 1 | Authors: | Heo, Y.S. | Deposit date: | 2016-06-16 | Release date: | 2016-11-09 | Last modified: | 2024-03-20 | Method: | X-RAY DIFFRACTION (2.8 Å) | Cite: | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy Nat Commun, 7, 2016
|
|
5GGQ
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 5ggq by Molmil](/molmil-images/mine/5ggq) | Crystal structure of Nivolumab Fab fragment | Descriptor: | nivolumab heavy chain, nivolumab light chain | Authors: | Heo, Y.S. | Deposit date: | 2016-06-16 | Release date: | 2016-11-09 | Last modified: | 2016-11-16 | Method: | X-RAY DIFFRACTION (1.9 Å) | Cite: | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy Nat Commun, 7, 2016
|
|
8GY5
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 8gy5 by Molmil](/molmil-images/mine/8gy5) | |
7VEN
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 7ven by Molmil](/molmil-images/mine/7ven) | Structure of burosumab Fab | Descriptor: | Burosumab Fab HC, Burosumab Fab LC | Authors: | Heo, Y.S. | Deposit date: | 2021-09-09 | Release date: | 2022-09-14 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (1.45 Å) | Cite: | Crystal Structure of the Fab Fragment of Burosumab To Be Published
|
|
8HU2
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 8hu2 by Molmil](/molmil-images/mine/8hu2) | Rattus Syntenin-1 PDZ domain with inhibitor | Descriptor: | (2~{S})-2-(9~{H}-fluoren-9-ylmethoxycarbonylamino)-3-(4-oxidanylidene-5~{H}-pyrimidin-2-yl)propanoic acid, Syntenin-1 | Authors: | Heo, Y, Lee, J, Yun, J.H, Lee, W. | Deposit date: | 2022-12-22 | Release date: | 2024-01-17 | Method: | X-RAY DIFFRACTION (1.6 Å) | Cite: | Crystal structure of STNPDZ with inhibitor at 1.60 Angstroms resolution. To Be Published
|
|
8GSI
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 8gsi by Molmil](/molmil-images/mine/8gsi) | Structure of the cobolimab Fab | Descriptor: | heavy chain, light chain, nanobody | Authors: | Heo, Y.S, Choi, S.B. | Deposit date: | 2022-09-06 | Release date: | 2023-09-06 | Method: | X-RAY DIFFRACTION (2.02 Å) | Cite: | Crystal structure of the Fab fragment of cobolimab, an investigational antibody targeting Tim-3 for immune-oncology. To Be Published
|
|
4HQ6
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 4hq6 by Molmil](/molmil-images/mine/4hq6) | BC domain in the presence of citrate | Descriptor: | Acetyl-CoA carboxylase 2 | Authors: | Heo, Y.S. | Deposit date: | 2012-10-25 | Release date: | 2013-10-09 | Last modified: | 2024-03-20 | Method: | X-RAY DIFFRACTION (2.7 Å) | Cite: | Structural Insights into the Regulation of ACC2 by Citrate Bull.Korean Chem.Soc., 34, 2013
|
|
6LSU
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 6lsu by Molmil](/molmil-images/mine/6lsu) | Crystal structure of Uso1-2 | Descriptor: | Intracellular protein transport protein USO1 | Authors: | Heo, Y.Y, Lee, H.H. | Deposit date: | 2020-01-20 | Release date: | 2021-01-27 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (2.7 Å) | Cite: | Crystal structures of Uso1 membrane tether reveal an alternative conformation in the globular head domain Sci Rep, 10, 2020
|
|
5Y9J
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 5y9j by Molmil](/molmil-images/mine/5y9j) | BAFF in complex with belimumab | Descriptor: | Tumor necrosis factor ligand superfamily member 13B, belibumab light chain, belimumab heavy chain | Authors: | Heo, Y.-S, Shin, W. | Deposit date: | 2017-08-25 | Release date: | 2018-02-21 | Last modified: | 2019-09-04 | Method: | X-RAY DIFFRACTION (2.05 Å) | Cite: | BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus. Nat Commun, 9, 2018
|
|
5Y9K
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 5y9k by Molmil](/molmil-images/mine/5y9k) | Structure of the belimumab Fab fragment | Descriptor: | belimumab heavy chain, belimumab light chain | Authors: | Heo, Y.-S, Shin, W. | Deposit date: | 2017-08-25 | Release date: | 2018-02-21 | Last modified: | 2019-09-04 | Method: | X-RAY DIFFRACTION (1.9 Å) | Cite: | BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus. Nat Commun, 9, 2018
|
|
6LST
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 6lst by Molmil](/molmil-images/mine/6lst) | Crystal straucture of Uso1-1 | Descriptor: | Intracellular protein transport protein USO1 | Authors: | Heo, Y.Y, Lee, H.H. | Deposit date: | 2020-01-20 | Release date: | 2021-01-27 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (2.94 Å) | Cite: | Crystal structures of Uso1 membrane tether reveal an alternative conformation in the globular head domain Sci Rep, 10, 2020
|
|
1UKH
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 1ukh by Molmil](/molmil-images/mine/1ukh) | Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125 | Descriptor: | 11-mer peptide from C-jun-amino-terminal kinase interacting protein 1, Mitogen-activated protein kinase 8 isoform 4 | Authors: | Heo, Y.-S, Kim, Y.K, Sung, B.-J, Lee, H.S, Lee, J.I, Seo, C.I, Park, S.-Y, Kim, J.H, Hyun, Y.-L, Jeon, Y.H, Ro, S, Lee, T.G, Cho, J.M, Hwang, K.Y, Yang, C.-H. | Deposit date: | 2003-08-23 | Release date: | 2004-08-30 | Last modified: | 2023-12-27 | Method: | X-RAY DIFFRACTION (2.35 Å) | Cite: | Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125 Embo J., 23, 2004
|
|
1UKI
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 1uki by Molmil](/molmil-images/mine/1uki) | Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125 | Descriptor: | 11-mer peptide from C-jun-amino-terminal kinase interacting protein 1, 2,6-DIHYDROANTHRA/1,9-CD/PYRAZOL-6-ONE, mitogen-activated protein kinase 8 isoform 4 | Authors: | Heo, Y.-S, Kim, Y.K, Sung, B.-J, Lee, H.S, Lee, J.I, Seo, C.I, Park, S.-Y, Kim, J.H, Hyun, Y.-L, Jeon, Y.H, Ro, S, Lee, T.G, Cho, J.M, Hwang, K.Y, Yang, C.-H. | Deposit date: | 2003-08-23 | Release date: | 2004-08-30 | Last modified: | 2023-12-27 | Method: | X-RAY DIFFRACTION (2.7 Å) | Cite: | Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125 Embo J., 23, 2004
|
|
5WUV
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 5wuv by Molmil](/molmil-images/mine/5wuv) | Crystal structure of Certolizumab Fab | Descriptor: | heavy chain, light chain | Authors: | Heo, Y.S, Lee, J.U, Son, J.Y, Shin, W, Yoo, K.Y. | Deposit date: | 2016-12-21 | Release date: | 2017-06-07 | Method: | X-RAY DIFFRACTION (1.952 Å) | Cite: | Molecular Basis for the Neutralization of Tumor Necrosis Factor alpha by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases Int J Mol Sci, 18, 2017
|
|
8WQJ
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 8wqj by Molmil](/molmil-images/mine/8wqj) | |
5X8M
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 5x8m by Molmil](/molmil-images/mine/5x8m) | PD-L1 in complex with durvalumab | Descriptor: | Programmed cell death 1 ligand 1, durvalumab heavy chain, durvalumab light chain | Authors: | Heo, Y.S, Lee, H.T. | Deposit date: | 2017-03-03 | Release date: | 2017-08-16 | Method: | X-RAY DIFFRACTION (2.661 Å) | Cite: | Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab Sci Rep, 7, 2017
|
|
5X8L
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 5x8l by Molmil](/molmil-images/mine/5x8l) | PD-L1 in complex with atezolizumab | Descriptor: | Programmed cell death 1 ligand 1, atezolizumab heavy chain, atezolizumab light chain | Authors: | Heo, Y.S, Lee, H.T. | Deposit date: | 2017-03-03 | Release date: | 2017-08-16 | Method: | X-RAY DIFFRACTION (3.1 Å) | Cite: | Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab Sci Rep, 7, 2017
|
|
7WJ5
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 7wj5 by Molmil](/molmil-images/mine/7wj5) | Cryo-EM structure of human somatostatin receptor 2 complex with its agonist somatostatin delineates the ligand binding specificity | Descriptor: | Gai1 antibody (scfv16), Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2, Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1, ... | Authors: | Heo, Y.S, Yoon, E.J, Jeon, Y.E, Yun, J.-H, Ishimoto, N, Woo, H, Park, S.Y, Song, J, Lee, W.T. | Deposit date: | 2022-01-05 | Release date: | 2022-07-13 | Method: | ELECTRON MICROSCOPY (3.72 Å) | Cite: | Cryo-EM structure of the human somatostatin receptor 2 complex with its agonist somatostatin delineates the ligand-binding specificity. Elife, 11, 2022
|
|
5WUX
![Download](/newweb/media/icons/dl.png) ![Visualize](/newweb/media/icons/hoh_3d.png)
![BU of 5wux by Molmil](/molmil-images/mine/5wux) | TNFalpha-certolizumab Fab | Descriptor: | Tumor necrosis factor alpha, heavy, light | Authors: | Heo, Y.S, Lee, J.U. | Deposit date: | 2016-12-21 | Release date: | 2017-06-07 | Method: | X-RAY DIFFRACTION (2.9 Å) | Cite: | Molecular Basis for the Neutralization of Tumor Necrosis Factor alpha by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases Int J Mol Sci, 18, 2017
|
|